P

Inventor

VON RAUMER MARKUS

CH20 patents
⚠️ This page may combine multiple inventors who share the name “VON RAUMER MARKUS”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

IDORSIA PHARMACEUTICALS LTD

13 patents
US11680058B2Jun 20, 2023

Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan

IDORSIA PHARMACEUTICALS LTD5 citations85
US10919881B2Feb 16, 2021

Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan

IDORSIA PHARMACEUTICALS LTD10 citations81
US11059803B2Jul 13, 2021

Crystalline form of N-[1-(5-cyano-pyridin-2- ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide

IDORSIA PHARMACEUTICALS LTD2 citations72
US10023560B2Jul 17, 2018

Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

IDORSIA PHARMACEUTICALS LTD3 citations72
US9914720B2Mar 13, 2018

Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

IDORSIA PHARMACEUTICALS LTD3 citations72
US9790208B2Oct 17, 2017

Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

IDORSIA PHARMACEUTICALS LTD4 citations72
US11365209B2Jun 21, 2022

Crystalline forms

IDORSIA PHARMACEUTICALS LTD1 citations70
US10730896B2Aug 4, 2020

Crystalline forms

IDORSIA PHARMACEUTICALS LTD1 citations70
US12297189B2May 13, 2025

Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan

IDORSIA PHARMACEUTICALS LTD0 citations62
US11555025B2Jan 17, 2023

Crystalline form of N-[1-(5-cyano-pyridin-2-ylmethyl)-1 H-pyrazol-3-yl]-2- [4-(1-trifluoromethyl-cyclopropyl)-phenyl-acetamide

IDORSIA PHARMACEUTICALS LTD0 citations62
US12534449B2Jan 27, 2026

Stable crystalline hydrate of clazosentan disodium salt

IDORSIA PHARMACEUTICALS LTD0 citations60
US11339148B2May 24, 2022

Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

IDORSIA PHARMACEUTICALS LTD0 citations51
US10351560B2Jul 16, 2019

Crystalline forms

IDORSIA PHARMACEUTICALS LTD0 citations49

BONHAM NICHOLAS

1 patent

ABELE STEFAN

1 patent

VIATRIS ASIA PACIFIC PTE LTD

1 patent

SOLVIAS AG

1 patent

RECORDATI IRELAND LTD

1 patent

GRUENENTHAL GMBH

1 patent

GRUSS MICHAEL

1 patent